[1]王卓.注射用鼠神经生长因子联合rt-PA静脉溶栓对急性脑梗死患者神经功能及血清NGF、MBP水平的影响[J].卒中与神经疾病杂志,2019,26(05):526-530.[doi:10.3969/j.issn.1007-0478.2019.05.005]
　Wang Zhuo..The effects of intravenous nerve growth factor and rt-PA intravenous thrombolysis on neurological function and serum levels of NGF and MBP in patients with acute cerebral infarction[J].Stroke and Nervous Diseases,2019,26(05):526-530.[doi:10.3969/j.issn.1007-0478.2019.05.005]
点击复制

注射用鼠神经生长因子联合rt-PA静脉溶栓对急性脑梗死患者神经功能及血清NGF、MBP水平的影响()
分享到：

《卒中与神经疾病》杂志[ISSN:1007-0478/CN:42-1402/R]

卷:
第26卷
期数:
2019年05期
页码:
526-530
栏目:
论 著
出版日期:
2019-10-20

文章信息/Info

Title:
The effects of intravenous nerve growth factor and rt-PA intravenous thrombolysis on neurological function and serum levels of NGF and MBP in patients with acute cerebral infarction
文章编号:
1007-0478(2019)05-0526-05
作者:
王卓
121000 辽宁省锦州市中心医院神经内科
Author(s):
Wang Zhuo.
Department of Neurology, Jinzhou Central Hospital, Jinzhou Liaoning 121000
关键词:
急性脑梗死 重组组织型纤维蛋白溶酶原激活剂 静脉溶栓 注射用鼠神经生长因子 神经功能 神经生长因子 髓鞘碱性蛋白 预后
Keywords:
Acute cerebral infarction rt-PA intravenous thrombolysis Mouse nerve growth factor for injection Neurological function NGF MBP Prognosis
分类号:
R743.3
DOI:
10.3969/j.issn.1007-0478.2019.05.005
文献标志码:
A
摘要:
目的 探讨注射用鼠神经生长因子联合重组组织型纤维蛋白溶酶原激活剂(rt-PA)静脉溶栓治疗急性脑梗死(ACI)的临床价值。方法 按照治疗方案不同将本院178例ACI患者(2014年8月-2018年9月)分为观察组与对照组,每组各89例; 在常规及对症治疗基础上对照组给予rt-PA静脉溶栓,观察组给予rt-PA静脉溶栓+注射用鼠神经生长因子治疗; 对比2组治疗前及治疗后不同时段(治疗1、2周后)神经功能(NIHSS评分)变化、治疗前及治疗2周后血清神经生长因子(Nerve growth factor,NGF)、髓鞘碱性蛋白(Myelin basic protein,MBP)水平变化、治疗期间不良反应发生率,治疗结束后随访3个月对比2组不良事件发生率及肢体运动功能(FMA评分)、生活自理能力(ADL评分)改善情况。结果(1)神经功能:治疗1、2周后2组NIHSS评分均较治疗前下降,且观察组下降幅度>对照组(P<0.05);(2)血清学指标:治疗2周后2组血清NGF、MBP水平均较治疗前改善(P<0.05),且观察组血清NGF水平高于对照组,MBP水平低于对照组(P<0.05);(3)安全性:治疗期间观察组不良反应发生率12.36%(11/89),与对照组8.99%(8/89)比较无显著差异(P>0.05);(4)不良事件:随访3个月观察组不良事件发生率3.37%(3/89),低于对照组11.24%(10/89)(P<0.05);(5)肢体运动功能及生活自理能力:随访3个月后2组FMA评分及ADL评分均较治疗前提高(P<0.05),且观察组优于对照组(P<0.05)。结论 注射用鼠神经生长因子联合rt-PA静脉溶栓治疗ACI效果显著,可有效促进患者神经功能恢复,调节血清NGF、MBP表达水平,有利于降低不良事件发生风险,改善患者肢体运动功能及生活自理能力,且有较好的安全性。
Abstract:
ObjectiveTo investigate the clinical value of intravenous nerve growth factor combined with rt-PA intravenous thrombolysis in the treatment of acute cerebral infarction(ACI).Methods According to different treatment options,178 patients with ACI(from August 2014 to September 2018)were divided into observation group and control group,89 cases in each group.On the basis of routine and symptomatic treatment,the control group was given rt-PA intravenous thrombolysis,and the observation group was given rt-PA intravenous thrombolysis + injection with mouse nerve growth factor.The neurological function(NIHSS score)was checked before and after treatment(1 week and 2 weeks after treatment),and serum nerve growth factor(Nerve growth factor,NGF)and myelin basic protein(Myelin basic protein,MBP)levels were measured before and after 2 weeks of treatment.The incidence of adverse reactions was observed during the treatment period and was followed up for 3 months after the end of treatment.The incidence of adverse events and the improvement of limb motor function(FMA score)and self-care ability(ADL score)were compared.Results(1)Neurological function:After 1 week and 2 weeks of treatment,the NIHSS scores of the two groups were lower than those before treatment,and the decrease of the observation group was greater than that of the control group(P<0.05).(2)Serological indicators:Two weeks after treatment,the serum levels of NGF and MBP were improved compared with those before treatment(P<0.05),and the serum NGF level of the observation group was higher than that of the control group,and the MBP level of the observation group was lower than that of the control group(P<0.05).(3)Safety:The incidence rate of 12.36%(11/89)of the observation group during the treatment period was not significantly different from 8.99%(8/89)of the control group(P>0.05).(4)Adverse events:During the 3 months of follow-up,the incidence of adverse events in the observation group was 3.37%( 3/89),the incidence of adverse events in the control group was 11.24%(10/89)(P<0.05);(5)Limb motor function and self-care ability:After 3 months of follow-up,the FMA score and ADL score of the two groups were higher than those before treatment( P< 0.05),and the FMA score and ADL score of the observation group were higher than those of the control group(P< 0.05).Conclusion Injection of rat nerve growth factor combined with rt-PA intravenous thrombolysis was effective in the treatment of ACI,which could effectively promote the recovery of neurological function,regulate the expression levels of serum NGF and MBP,reduce the risk of adverse events,improve the limb motor function and self-care ability and the security were better.

参考文献/References:

[1] 陈晓红,张晓程,楼敏.急性脑梗死静脉影像研究进展[J].中国实用内科杂志,2017,37(11):953-956. [2] Naess H,Kurtz M,Thomassen L,et al.Serial NIHSS scores in patients with acute cerebral infarction[J].Acta Neurol Scand,2016,133(6):415-420. [3] 江思德,唐明山,肖静,等.脑梗死急性期治疗临床研究进展[J].医学综述,2016,22(8):1513-1515. [4] Sun X,Berthiller J,Derex L,et al.Post-thrombolysis haemostasis changes after rt-PA treatment in acute cerebral infarct.Correlations with cardioembolic aetiology and outcome[J].J Neurol Sci,2015,349(1/2):77-83. [5] 刘静,吴雅坤.急性脑梗死rt-PA溶栓治疗进展[J].河北医科大学学报,2016,37(3):355-357. [6] 王炜,赵海霞.注射用鼠神经生长因子对大鼠缺血脑组织神经生长因子及脑源性神经营养因子表达的影响[J].中国药物与临床,2017,17(2):171-174. [7] 姜炎,连亚军.鼠神经生长因子对急性脑梗死大鼠炎性因子与神经功能的影响[J].中华实验外科杂志,2016,33(7):1819-1821. [8] 中华医学会神经病学分会脑血管病学组急性缺血性脑卒中诊治指南撰写组.中国急性缺血性脑卒中诊治指南2010[J].中华医学信息导报,2010,25(14):16-19. [9] Ali K,Cheek E,Sills S,et al.Development of a conversion factor to facilitate comparison of National Institute of Health Stroke Scale scores with Scandinavian stroke scale scores[J].Cerebrovascular Diseases,2007,24(6):509-515. [10] 巫嘉陵,安中平,王世民,等.脑卒中患者日常生活活动能力量表的信度与效度研究[J].中国现代神经疾病杂志,2009,9(5):464-468. [11] 陈瑞全,吴建贤,沈显山.中文版Fugl-Meyer运动功能评定量表的最小临床意义变化值的研究[J].安徽医科大学学报,2015,50(4):519-521,522. [12] 兰天.呼日勒特木尔.脑卒中流行病学现状及遗传学研究进展[J].疑难病杂志,2015,14(9):986-989. [13] 王钦鹏,苏丹丹,张燕菊,等.中性粒细胞-淋巴细胞比值评价急性脑梗死临床预后的研究进展[J].国际神经病学神经外科学杂志,2016,43(5):484-487. [14] Camerlingo M,Tudose V,Tognozzi M,et al.Predictors of re-canalisation in acute cerebral infarction from occlusion of the terminal internal carotid artery or of the middle cerebral artery mainstem treated with thrombolysis[J].Int J Neurosci,2014,124(3):199-203. [15] 王允,代大伟,范宇威,等.急性脑梗死溶栓治疗的临床进展[J].现代生物医学进展,2017,17(26):5194-5196. [16] 陈静霞.阿替普酶静脉溶栓治疗与非溶栓治疗对急性脑梗死患者神经功能的影响研究[J].海南医学院学报,2017,23(2):244-247. [17] 赵秀欣,穆利春,马丽芳.rt-PA静脉溶栓治疗急性脑梗死临床分析[J].中国循证心血管医学杂志,2016,8(4):486-488. [18] 赵宏,汪立松,童巧文.阿替普酶静脉溶栓对急性脑梗死患者神经功能、炎症及氧化应激反应的影响[J].中华全科医学,2017,15(8):1345-1347. [19] 王朝侠,张欢瑞,程格庆,等.Rt-PA静脉溶栓治疗急性脑梗死的疗效及对血清IL-6,IL-17及VEGF水平的影响[J].现代生物医学进展,2017,17(21):149-152. [20] 刘芳,林金生,唐颖,等.rt-PA治疗急性脑梗死的近期临床疗效及其影响因素分析[J].现代生物医学进展,2017,17(8):1527-1529. [21] 杨帆,陈俊良,周格知,等.鼠神经生长因子治疗急性脑梗死的临床疗效研究[J].中华全科医学,2018,16(6):47-49. [22] Singh S,Sayers S,Walter JS,et al.Hypertrophy of neurons within cardiac ganglia in human,canine,and rat heart failure:the potential role of nerve growth factor[J].J Am Heart Assoc,2013,2(4):e000210. [23] 何雪冬,赵秋玲,于国伟.脑梗死血清学危险因素流行病学研究进展[J].西北民族大学学报(自然科学版),2016,37(4):58-61,65. [24] 徐静,葛汝丽,曹晓雨.神经生长因子在治疗脑梗死中的研究进展[J].卒中与神经疾病,2018,25(1):101-104. [25] 柳丰慧,张可帅.血清白介素6、基质金属蛋白酶9、基质金属蛋白酶抑制剂1、超敏C反应蛋白及神经生长因子水平与急性脑梗死患者神经功能缺损程度的关系研究[J].实用心脑肺血管病杂志,2017,25(1):35-38. [26] 夏翠萍.急性脑梗死患者监测Ngb、BDNF和MBP的临床意义[J].临床误诊误治,2016,29(12):81-84. [27] 李娜娜,丰宏林.急性脑梗死患者静脉溶栓治疗及预后的研究进展[J].医学综述,2017,23(16):3221-3225. [28] 夏楠,任彩丽,王红星,等.脑梗死急性期康复训练流程对患者运动功能和日常生活活动能力改善程度的影响[J].中国康复医学杂志,2017,32(4):396-401.

备注/Memo

备注/Memo:
(2019-03-15收稿)
更新日期/Last Update: 2019-10-20